: In a significant step towards addressing the complexities of Parkinson’s Disease (PD), BioVie has announced an alignment with the FDA regarding a pivotal clinical trial aimed at assessing the efficacy of Bezisterim (NE3107). This article discusses the implications of the SUNRISE-PD trial which evaluates both motor and non-motor symptoms in a population of approximately 60 patients newly diagnosed and untreated with carbidopa/levodopa. Additionally, the analysis elaborates on the current context of BioVie Inc’s operational performance, especially in light of its revenue stagnation linked to corporate clients. Parkinson’s Disease is a progressive neurodegenerative disorder characterized by its hallmark...
BioVie Inc. Unveils Protocol Design for SUNRISE-PD Phase 2 Trial of Bezisterim in Early Parkinson’s Disease at ATMRD 2024BioVie Inc. has made significant strides in the treatment of Parkinson’s disease with its recent announcement at the Annual Meeting on Targeted Molecular- and Radiotherapy Development (ATMRD) 2024. The company presented a detailed protocol design for its upcoming SUNRISE-PD Phase 2 clinical trial, which will evaluate the efficacy of bezisterim (NE3107) on both motor and non-motor symptoms in patients with early-stage Parkinson s disease who have not yet been treated with the conventional carbidopa/levodopa therapy. This clinical trial marks another significant milestone in BioVie’s ...
BioVie s Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson s Disease PatientsFull Dataset from Phase 2a trial in Parkinson s Disease suggest patients treated with bezisterim experienced significant improvements in both non-motor symptoms and motor control while placebo-treated patients worsenedDuring the corresponding time, Biovie Inc also witnessed substantial growth in revenue from its corporate clientsParkinson s Disease is a debilitating neurological condition that affects millions of people around the world, impairing their ability to control movement and causing non-motor symptoms such as sleep disturbances, fatigue, and restless leg syndrome. Howev...
In recent years, there has been a surge in research exploring innovative therapeutic options for various debilitating diseases. The articles mentioned above shed light on the groundbreaking potential of Bezisterim (NE3107), a novel compound developed by BioVie, which holds promise for the treatment of Long COVID, Parkinson s disease, and Alzheimer s disease. This comprehensive review aims to analyze the findings from studies conducted by BioVie, evaluate the impact of Bezisterim (NE3107) on different patient populations, and discuss its potential implications for future therapeutic strategies.Bezisterim (NE3107) for the Treatment of Long COVID:The COVID-19 pandemic has left a significant number of individual...
BioVie s NE3107 Shows Promise for Improving Symptoms in Parkinson s Disease Patients and Potential Benefits for Alzheimer s Disease PatientsData from a Phase 2a trial conducted by BioVie Inc has demonstrated potential improvements in both motor and non-motor symptoms for patients with Parkinson s disease. These findings will be presented at the upcoming International Conference on Alzheimer s and Parkinson s Diseases in 2024. Additionally, this drug may have the potential to realign physiological processes for patients with Alzheimer s disease.The trial included a group of Parkinson s disease patients who were treated with NE3107, a drug developed by BioVie Inc, and another group who were given a placebo. Th...
BioVie Inc., a biopharmaceutical company focused on developing innovative therapies for serious neurological diseases, recently released encouraging efficacy data from a Phase 3 clinical trial of NE3107 in patients with mild to moderate Alzheimer s disease. The results suggest that NE3107, BioVie s investigational drug, is biologically active and could potentially have a positive impact on cognitive, functional, and biomarker endpoints. The trial enrolled a total of 57 per-protocol patients, and the data obtained from these individuals displayed a positive trending effect of NE3107. The drug is believed to have demonstrated efficacy in improving cognitive function, functional abilities, and certain ...
Sources:
Biovie Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Biovie Inc’s corporate clients.
For your research, we’ve provided 9 tables on Biovie Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
